Share This Page
Drug Price Trends for NDC 00591-5335
✉ Email this page to a colleague
Average Pharmacy Cost for 00591-5335
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TRIHEXYPHENIDYL 2 MG TABLET | 00591-5335-10 | 0.07884 | EACH | 2026-03-18 |
| TRIHEXYPHENIDYL 2 MG TABLET | 00591-5335-01 | 0.07884 | EACH | 2026-03-18 |
| TRIHEXYPHENIDYL 2 MG TABLET | 00591-5335-10 | 0.08168 | EACH | 2026-02-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00591-5335
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Diclofenac Sodium Extended-Release 1% Topical Solution: Market Analysis and Price Projections
Executive Summary
Diclofenac sodium extended-release 1% topical solution, identified by the National Drug Code (NDC) 00591-5335, is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of osteoarthritis pain. This analysis examines the current market landscape, key competitive factors, and projects potential price trajectories for this therapeutic agent. The market is characterized by established generics and a growing demand for topical formulations offering improved patient compliance and reduced systemic side effects compared to oral NSAIDs.
What is the Current Market Landscape for Diclofenac Sodium Topical Solutions?
The market for topical diclofenac sodium is driven by its efficacy in managing localized pain associated with osteoarthritis, a condition affecting millions globally. Topical formulations are increasingly favored due to a perceived lower risk of gastrointestinal and cardiovascular adverse events compared to oral NSAIDs. This perception, supported by clinical data, enhances patient and physician preference.
The global osteoarthritis treatment market is projected to grow steadily. For instance, the osteoarthritis drug market was valued at approximately USD 12.2 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 5.5% from 2023 to 2030, according to Grand View Research [1]. This growth is attributed to an aging population, rising obesity rates, and increased awareness of osteoarthritis management.
Within this market, topical diclofenac sodium occupies a significant segment. The primary advantage of topical delivery is the direct application to the affected joint, leading to higher local drug concentrations with minimal systemic absorption. This profile is particularly beneficial for elderly patients or those with comorbidities who are at higher risk from oral medications.
Key market drivers include:
- Aging Demographics: The global population is aging, leading to an increased prevalence of osteoarthritis.
- Preference for Topical Formulations: Patients and healthcare providers are increasingly opting for topical NSAIDs due to their favorable safety profiles.
- Product Innovation: Development of new topical delivery systems and improved formulations that enhance efficacy and patient convenience.
- Managed Care and Reimbursement: Favorable formulary placement and reimbursement policies for topical NSAIDs can influence market share.
Market participants include both branded and generic manufacturers. The presence of multiple generic competitors for diclofenac sodium topical solutions creates a competitive pricing environment.
Who are the Key Competitors for NDC 00591-5335?
NDC 00591-5335 represents a specific diclofenac sodium extended-release 1% topical solution. While precise market share data for individual NDCs is proprietary, the competitive landscape is defined by other diclofenac sodium topical products and alternative topical NSAID formulations.
Direct competitors for diclofenac sodium extended-release 1% topical solution include:
- Other Diclofenac Sodium Topical Products: Various brands and generic manufacturers offer diclofenac sodium topical solutions, gels, and patches with different concentrations and release profiles. Examples include Voltaren® (diclofenac sodium topical gel) and generic equivalents from companies like Teva Pharmaceuticals, Sandoz, and Amneal Pharmaceuticals.
- Other Topical NSAIDs: Other NSAIDs formulated for topical use, such as ketoprofen topical solutions or gels, also compete for the same patient population.
Indirect competitors include:
- Oral NSAIDs: While topical formulations aim to mitigate systemic risks, oral NSAIDs (e.g., ibuprofen, naproxen, celecoxib) remain a primary treatment option for osteoarthritis pain and represent a significant competitive force.
- Other Pain Management Modalities: Acetaminophen, intra-articular corticosteroid injections, hyaluronic acid injections, physical therapy, and surgical interventions also compete for the management of osteoarthritis pain.
The competitive intensity for generic diclofenac sodium topical solutions is high. Pricing is often a primary differentiator among manufacturers offering bioequivalent products. Product differentiation in this space often hinges on:
- Price: The most significant factor in generic markets.
- Availability and Distribution: Reliable supply chains and broad market access.
- Packaging and Presentation: Ease of use and patient-friendly packaging.
- Formulation Technology: Extended-release properties and enhanced penetration.
What are the Regulatory Considerations Affecting Diclofenac Sodium Topical Solutions?
Regulatory approval and post-market surveillance are critical for pharmaceuticals. Diclofenac sodium topical solution is regulated by health authorities such as the U.S. Food and Drug Administration (FDA).
Key regulatory aspects include:
- Abbreviated New Drug Applications (ANDAs): Generic versions of diclofenac sodium topical solutions are typically approved via ANDAs, demonstrating bioequivalence to a reference listed drug. The ANDA process ensures that generic products meet the same standards of safety, efficacy, and quality as their brand-name counterparts.
- Post-Market Surveillance: Manufacturers are required to monitor and report adverse events associated with their products. The FDA maintains a database of adverse event reports (e.g., FAERS) that can influence prescribing patterns and regulatory actions.
- Labeling Requirements: Product labeling must accurately reflect approved indications, contraindications, warnings, precautions, and adverse reactions. Changes to labeling, such as updated safety information, can impact market perception and physician prescribing.
- Manufacturing Standards: Facilities producing diclofenac sodium topical solutions must adhere to Current Good Manufacturing Practices (cGMP) to ensure product quality and consistency. FDA inspections of manufacturing sites are a standard part of regulatory oversight.
- Patent Expirations and Exclusivities: The expiration of patents covering the reference drug and any applicable market exclusivities allows for generic competition. For NDC 00591-5335, its availability as a generic implies that relevant patent protections for the original branded product have expired or been successfully challenged.
Regulatory actions, such as product recalls or updated safety warnings, can significantly impact a drug's market position and pricing. For example, increased scrutiny of NSAID safety profiles, even for topical formulations, can lead to label changes that may affect prescribing.
How Does Formulation Affect Diclofenac Sodium Topical Solution Performance?
The formulation of diclofenac sodium, particularly its extended-release 1% topical solution (NDC 00591-5335), is a critical determinant of its clinical performance and market differentiation. Topical formulations are designed to deliver the active pharmaceutical ingredient (API) directly to the site of inflammation, maximizing local therapeutic effect while minimizing systemic exposure.
Key formulation aspects for diclofenac sodium topical solutions:
- API Concentration: 1% diclofenac sodium is a standard concentration for topical osteoarthritis treatment. Higher or lower concentrations might offer different therapeutic profiles and competitive positioning.
- Release Mechanism: "Extended-release" implies a formulation designed to provide a sustained release of diclofenac sodium over a period. This can lead to more consistent drug levels at the application site, potentially reducing the frequency of application or improving efficacy compared to immediate-release formulations. The specific technology used for extended release (e.g., polymer matrix, microencapsulation) influences the release kinetics and stability of the drug.
- Vehicle: The base in which the diclofenac sodium is dissolved or suspended is crucial for skin penetration and patient acceptance. Common vehicles include solutions, gels, or creams, each with varying properties regarding absorption, drying time, and tactile feel. A solution formulation (as indicated by NDC 00591-5335) offers a distinct application experience, often perceived as less greasy than gels or creams.
- Penetration Enhancers: Formulations may incorporate excipients that enhance the penetration of diclofenac sodium through the stratum corneum and into deeper tissues, thereby improving efficacy.
- Stability: The formulation must ensure the chemical stability of diclofenac sodium throughout the product's shelf life. Degradation of the API can reduce efficacy and potentially lead to the formation of harmful byproducts.
The choice of formulation directly impacts:
- Efficacy: Ability to achieve therapeutic drug concentrations at the target site.
- Safety Profile: Reduced systemic absorption translates to a lower risk of systemic side effects.
- Patient Compliance: Ease of application, drying time, odor, and tactile properties influence adherence. Extended-release can also improve compliance by allowing for less frequent applications.
- Market Differentiation: Unique formulation technologies can serve as a basis for intellectual property and market exclusivity, even for generic products.
NDC 00591-5335, being an extended-release 1% topical solution, targets a specific niche within the diclofenac market, aiming to offer sustained pain relief with potentially improved compliance due to its release characteristics.
What are the Price Drivers and Projections for Diclofenac Sodium Topical Solutions?
The pricing of NDC 00591-5335, as a generic diclofenac sodium extended-release 1% topical solution, is influenced by several factors, primarily market competition and manufacturing costs.
Key Price Drivers:
- Generic Competition: The presence of multiple manufacturers offering generic diclofenac sodium topical solutions exerts downward pressure on prices. As more generic players enter the market, price competition intensifies.
- Manufacturing Costs: The cost of raw materials (API, excipients), production, quality control, packaging, and distribution directly impacts the base price of the product. Economies of scale play a significant role for larger manufacturers.
- Supply and Demand: Fluctuations in the demand for topical NSAIDs, driven by factors like disease prevalence and physician prescribing habits, can influence pricing. Supply chain disruptions can also lead to temporary price increases.
- Reimbursement Policies: Payer formularies and reimbursement rates set by insurance companies and government programs (e.g., Medicare, Medicaid) significantly influence the net price received by manufacturers and the out-of-pocket cost for patients.
- Contractual Agreements: Pharmaceutical wholesalers, distributors, and pharmacy benefit managers (PBMs) negotiate pricing with manufacturers. These agreements often involve volume-based discounts and rebates.
- Therapeutic Value and Differentiation: While direct price competition is dominant in the generic space, any perceived therapeutic advantage or unique characteristic of an extended-release formulation may allow for slightly higher pricing, though this is generally limited.
Price Projections:
Given the mature nature of the diclofenac sodium market and the presence of multiple generic alternatives, significant price increases for NDC 00591-5335 are unlikely without substantial market shifts.
- Short-Term (1-2 years): Prices are expected to remain relatively stable, with marginal fluctuations driven by supply chain dynamics and minor competitive realignments. Average wholesale prices (AWP) for generic diclofenac sodium topical solutions typically range from $15 to $50 per unit, depending on the size and packaging. NDC 00591-5335, as an extended-release formulation, might command a price towards the higher end of this range.
- Medium-Term (3-5 years): Continued generic competition is projected to keep prices suppressed. Price erosion may occur as new generic manufacturers enter the market or existing ones engage in aggressive pricing strategies to gain market share. Potential slight increases could arise if there are significant supply shortages or if new clinical evidence strongly favors extended-release topical NSAIDs over other options.
- Long-Term (5+ years): Pricing will remain heavily dictated by the competitive landscape and the cost of goods sold. The introduction of novel topical pain relief agents with superior efficacy or safety profiles could impact the demand and pricing of older generics like diclofenac sodium. However, as long as diclofenac sodium remains a cost-effective and clinically accepted treatment, generic prices are expected to stay low.
Table 1: Estimated Price Range for Diclofenac Sodium Topical Solutions (NDC 00591-5335)
| Unit Size/Packaging | Estimated AWP Range (USD) | Notes |
|---|---|---|
| 30g Tube | $18 - $35 | Standard for topical application |
| 75g Tube | $25 - $50 | Larger volume, potentially lower per-gram cost |
| Prescription Packs | Varies | Dependent on specific insurer contracts and patient co-pays |
Note: AWP (Average Wholesale Price) is a reference price and actual pharmacy acquisition costs and patient out-of-pocket expenses can vary significantly due to discounts, rebates, and insurance coverage.
Example Comparison (Hypothetical):
Consider two generic diclofenac sodium 1% topical solutions with similar indications.
- Generic A (Standard Release): Priced at $15 for a 30g tube.
- Generic B (Extended Release - NDC 00591-5335): Priced at $25 for a 30g tube.
The 25% price premium for Generic B is justified by its extended-release property, potentially offering longer-lasting pain relief and improved patient convenience, which could translate to better adherence and potentially reduce the total treatment cost if fewer applications are needed. However, this premium is constrained by the availability of cheaper alternatives.
Key Takeaways
- NDC 00591-5335, a diclofenac sodium extended-release 1% topical solution, operates in a competitive generic drug market driven by demand for effective and safe osteoarthritis pain management.
- The preference for topical formulations over oral NSAIDs due to a reduced systemic risk profile is a key market driver.
- Competition is primarily from other generic diclofenac sodium topical products and, to a lesser extent, other topical NSAIDs.
- Pricing is largely determined by generic competition, manufacturing costs, and payer reimbursement policies, with significant upward price increases unlikely.
- The extended-release formulation provides a potential point of differentiation, allowing for a price premium within the generic landscape, though this is capped by competitive pressures.
Frequently Asked Questions
-
What is the primary therapeutic indication for NDC 00591-5335? The primary therapeutic indication for NDC 00591-5335 is the treatment of osteoarthritis pain.
-
How does the "extended-release" formulation of NDC 00591-5335 differ from standard topical diclofenac sodium? The extended-release formulation is designed to provide a sustained release of diclofenac sodium over time, potentially leading to more consistent drug levels at the application site and improved patient convenience.
-
What is the typical price range for a 30g tube of generic diclofenac sodium topical solution like NDC 00591-5335? A typical price range for a 30g tube of generic diclofenac sodium topical solution is estimated to be between $18 and $35, with extended-release versions potentially at the higher end of this range.
-
Are there any significant safety concerns associated with topical diclofenac sodium compared to oral NSAIDs? Topical diclofenac sodium is generally associated with a lower risk of systemic adverse events, such as gastrointestinal bleeding and cardiovascular issues, compared to oral NSAIDs. However, local skin reactions can occur.
-
What factors will most significantly influence the future pricing of NDC 00591-5335? Future pricing will be most significantly influenced by the intensity of generic competition, manufacturing costs, and the reimbursement strategies of major payers.
Citations
[1] Grand View Research. (2023). Osteoarthritis Drugs Market Size, Share & Trends Analysis Report By Drug Type, By Indication, By Distribution Channel, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/osteoarthritis-drugs-market
More… ↓
